Early-Onset Neonatal Sepsis: Group B Streptococcal Compared to *E. coli* Disease

Renoldner B1, Hofer N1 and Resch B1,2,*

1Research Unit for Neonatal Infectious Diseases and Epidemiology, Medical University of Graz, Austria
2Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Austria

*Corresponding author: Bernhard Resch, Division of Neonatology, Department of Pediatrics Medical University of Graz, Auenbruggerplatz 34/2, 8036 Graz, Austria, Tel: ++43 316 385 81134; Fax: ++43 316 386 12678; E-mail: bernhard.resch@medunigraz.at

Rec date: September 30, 2015; Acc date: October 20, 2015; Pub date: October 30, 2015

Abstract

**Background:** Early onset sepsis (EOS) of the newborn is a severe disease and associated with high morbidity and mortality. Aim of the study was to compare perinatal, short-term outcome and laboratory data of neonates with early-onset sepsis (EOS) either due to *Group B Streptococcus* (GBS) or *Escherichia coli* (*E. coli*) infection.

**Methods:** Retrospective cohort analysis of all neonates with culture proven GBS and *E. coli* EOS born between 1993 and 2011 and hospitalized at the NICU of the Medical University of Graz, Austria. Data were analyzed regarding perinatal, laboratory and short-term outcome data.

**Results:** During the study period 100 neonates with EOS due to GBS and 11 neonates with *E. coli* infection were hospitalized at our NICU. Perinatal and short-term outcome data differed between GBS and *E. coli* infection regarding gestational age (median 38 vs. 32 weeks, \(p=0.005\)), birth weight (median 3095 vs. 1836 grams, \(p=0.031\)), presence of hypothermia (0 vs. 18%, \(p=0.009\)), duration of mechanical ventilation (4 vs. 8 days, \(p=0.018\)), duration of therapy with supplemental oxygen (9 vs. 2 days, \(p=0.031\)), length of hospitalization (15 vs. 22 days, \(p=0.039\)), presence of chorioamnionitis (17 vs. 46%, \(p=0.041\)) and maternal fever (2 vs. 18%, \(p=0.049\)). Mortality rates did not differ significantly (6 vs. 18%, \(p=0.180\)). Laboratory data regarding white blood cell count, IT-ratio, and CRP value were not different between groups within the first 72 hours of life. There was a significant decrease of GBS sepsis during the study period (\(p=0.014\)).

**Conclusion:** Main differences between GBS and *E. coli* infections were due to higher rates of preterm birth in the *E. coli* group, clinical and laboratory characteristics only differed marginally.

Keywords: Early-onset sepsis; *Escherichia coli*; Group B streptococcus; Neonate; Preterm infant

Introduction

Early onset sepsis (EOS) of the newborn is a severe disease and associated with high morbidity and mortality. At present *Group B Streptococcus* (GBS) and *Escherichia coli* (*E. coli*) are the most common pathogens in developing countries, most infants with GBS are born at term, infants with *E. coli* are more common born preterm [1,2]. After the implementation of preventing strategies based on administration of intrapartum antibiotic prophylaxis the incidence of GBS decreased over the last 15 years from 1.7 cases per 1,000 live births in the early 1990s to 0.34-0.37 cases per 1,000 live births in the last years [3]. In 1996 CDC recommended either a risk-based approach for intrapartum administration of antibiotics or an universal screening for vaginal or rectal GBS colonization for all pregnant woman between 35 and 37 weeks of gestation. In the revised guidelines of 2002 CDC only recommended the universal screening. In Austria there is still a risk-based approach and no universal GBS screening [4,5]. There are concerns that the widespread use of antibiotics could increase the frequencies of non-GBS or antimicrobial-resistant pathogens [6-9].

Aim of the study was to compare perinatal data, morbidities, mortality, therapies and laboratory data of neonates with EOS either due to GBS or *E. coli* infection.

Methods

**Study design**

This was a retrospective study at the NICU of the Pediatric Department of the Medical University of Graz. Data were collected between 1993 and 2011. Inclusion criteria were a culture proven sepsis caused by GBS or *E. coli* diagnosed within the first 72 hours of life. Exclusion criteria were missing or incomplete data, a culture-negative clinical sepsis and an unknown state of infection.

Analyzed neonatal variables included sex, gestational age (GA), birth weight (BW), preterm birth, Apgar scores at 1.5 and 10 minutes, clinical signs (tachycardia, bradycardia, tachypnea, apnea, hypotension, hypothermia, fever), therapy (mechanical ventilation (CPAP included), duration of mechanical ventilation, high frequency oscillation, surfactant, nitrogen oxide, immunoglobulin, catecholamine), morbidities (respiratory distress syndrome, pneumonia, pneumothorax, persistent pulmonary hypertension of the newborn, seizures, periventricular leukomalacia, intra-/periventricular...
hemorrhage, hypoxic ischemic encephalopathy, septic shock, multiorgan failure, disseminated intravascular coagulation, renal failure, mortality) length of hospitalization and laboratory parameters (C-reactive protein - CRP, white blood cell count, IT-ratio) on the 1st, 2nd and 3rd day of life. Maternal variables included prolonged rupture of membranes (PROM >18 hours), preterm premature rupture of the membranes (PPROM), presence of chorioamnionitis and maternal fever.

Definition of EOS

EOS was defined as culture proven sepsis (a positive blood or cerebrospinal fluid culture) within the first 72 hours of life.

In addition to a positive blood or cerebrospinal fluid culture they had to meet the following criteria: clinical signs of sepsis in ≥ 1 with either ≥ 1 maternal risk factor or ≥ 1 abnormal laboratory marker.

Clinical signs of sepsis included: respiratory symptoms (apnea, tachypnea (>60/min), retractions, cyanosis, and respiratory distress), cardiocirculatory symptoms (tachycardia (>180/min) or bradycardia (<100/min), arterial hypotension) neurological symptoms (irritability, lethargy, and seizures), poor skin color or prolonged capillary refilling time (more than 2 seconds), fever or hypothermia (core temperature >38°C or <36°C).

Maternal risk factors included; PROM (more than 18 hours) or PPROM, clinical chorioamnionitis (uterine tenderness or foul-smelling amniotic fluid, maternal leucocytosis >12,000/μL and maternal or fetal tachycardia) and maternal fever >38°C during labor. Laboratory sepsis marker were white blood cell (WBC) count >34,000/μL or <9000/μL, absolute neutrophil count >14,400/μL or <7,000/μL (<2,000/μL during the first 24 h of life), CRP >8 mg/L, immature-to-total neutrophil ratio (IT ratio) >0.2 [10-12].

| Variable | GBS (n=100) cases | E. coli (n=11) cases | P value |
|----------|------------------|---------------------|--------|
| male | 57 (57) | 6 (54.5) | n.s |
| gestational age (weeks)³ | 38 | 32 | 0.005 |
| birth weight (g)³ | 3095 | 1836 | 0.031 |
| APGAR 1³ | 8 | 7.5 | n.s |
| APGAR 5³ | 9 | 8 | 0.025 |
| APGAR 10³ | 10 | 8 | 0.024 |

Risk factors

- preterm
- Rupture of membranes >18 h
- chorioamnionitis
- maternal fever >38°C

Data are given as n(%). n.s = not significant.

³data are given as median

Table 1: Perinatal data of study population.

Statistical analysis

Statistical analyses were performed with SPSS version 20 (SPSS, Chicago, IL, USA). Descriptive statistics were obtained for all categorical variables. Statistical significance was determined for unadjusted comparisons by Mann-Whitney-U-test for continuous variables and by Fisher’s exact test for categorical variables. A univariate analysis was performed and the significance level was set at p<0.05. The Pearson correlation coefficient was used to analyze the association between the frequency of occurrence of pathogens and the time.

Results

During the study period 100 neonates with EOS due to GBS and 11 neonates with E. coli infection were hospitalized at our NICU.

Forty-two percent of the infants with GBS and 73 percent with E. coli EOS were born preterm. Thirteen percent of the infants with GBS and 36 percent with E. coli infection had a very-low-birth-weight (VLBW, < 1500 grams). GBS was the most common pathogen among term (95%), preterm (84%) and VLBW (76%) infants.

There was a significant reduction of GBS during the study period (p=0.014). The Pearson correlation coefficient was -0.601.

In comparison to neonates with GBS sepsis, neonates with E. coli sepsis had a lower GA and a lower BW. The risk factors chorioamnionitis and maternal fever occurred more frequently in the E. coli group. Perinatal data are shown in Table 1.

Clinical signs, therapy, morbidities and the length of hospitalization are shown in Table 2. There were significant differences regarding hypothermia, duration of mechanical ventilation and length of hospitalization.

Laboratory data not differed between groups (Table 3).

Discussion

In spite of the implementation of preventing strategies, GBS remained the leading cause of EOS among term, preterm and VLBW infants in our study. There was a significant decrease of GBS sepsis over the study period, but no increase of EOS caused by E. coli neither among term nor preterm or VLBW infants like in other studies [13,14]. Intrapartum antibiotic treatment is suggested to cause negative blood cultures and thus, maybe some infants with culture proven EOS were not identified.

Stoll et al. [1] reported that neonates with GBS sepsis were mostly born at term, and those with E. coli sepsis preterm. In their study the risk factors chorioamnionitis and premature rupture of membranes occurred more frequently among infants with E. coli sepsis compared to infants with GBS sepsis. Also mortality rates were higher among infants with E. coli EOS, but differences were not significant anymore after adjustment for GA. Mayor-Lynn et al. [15] reported that E. coli sepsis cases had a lower birth weight, a higher percentage with 5-minute Apgar score <7, and a longer stay in the hospital neonatal intensive care unit and required mechanical ventilation more frequently. Death after early-onset neonatal sepsis with E. coli was also more frequent. Additionally the risk factor chorioamnionitis was more frequently found among neonates with GBS sepsis. The authors concluded that EOS with E. coli was associated with more morbidity and a higher mortality rate compared with early-onset GBS disease.
Our results were comparable to those reported by Stoll et al. [1] and Mayor-Lynn et al. [15]. Most infants with GBS sepsis were born at term and those with *E. coli* sepsis preterm. In comparison to neonates with GBS sepsis, neonates with *E. coli* sepsis had a lower BW, a lower GA and a longer stay at the neonatal ward. The Apgar scores at 5 and 10 minutes were lower. Mortality rate did not differ significantly between the two groups. The risk factor chorioamnionitis and maternal fever occurred more frequently in the *E. coli* group. We found no difference regarding the frequency of mechanical ventilation between the two groups, but neonates with *E. coli* sepsis had a longer duration of ventilation and longer therapy with supplemental oxygen. The higher rate of hypothermia in the *E. coli* group might be the result of the higher rate of preterm birth, as far as preterm infants are known

| Variable                              | GBS cases (n=100) | *E. coli* cases (n=11) | P value |
|---------------------------------------|-------------------|------------------------|---------|
| Clinical signs                        |                   |                        |         |
| tachykardia                           | 12 (14.5)         | 1 (11.1)               | n.s     |
| bradykardia                           | 2 (2.4)           | 1 (11.1)               | n.s     |
| tachypnea                             | 44 (72.1)         | 5 (83.3)               | n.s     |
| apnea                                 | 21 (21)           | 3 (27.3)               | n.s     |
| hypotension                           | 39 (39)           | 6 (54.5)               | n.s     |
| hypothermia                           | 0 (0)             | 2 (18.2)               | 0.009   |
| fever                                 | 14 (14)           | 0                      | n.s     |
| Therapy                               |                   |                        |         |
| mechanical ventilation (CRAP included)| 66 (66.7)         | 10 (90.9)              | n.s     |
| duration of mechanical ventilation (d) | 4                  | 8                      | 0.019   |
| duration of therapy with supplemental oxygen (d) | 2                  | 9                      | 0.031   |
| high frequency oscillation            | 7(7.1)            | 2(18.2)                | n.s     |
| surfactant                            | 38 (38.8)         | 8 (72.7)               | n.s     |
| nitrogen oxide                        | 8 (8.2)           | 0 (0)                  | n.s     |
| interleukinoligulin                   | 19 (19.2)         | 2 (18.2)               | n.s     |
| catecholamine                         | 39 (39)           | 6(54.5)                | n.s     |
| Morbidities                           |                   |                        |         |
| respiratory distress syndrome         | 26 (26)           | 6(54.5)                | n.s     |
| pneumonia                             | 11 (11)           | 0 (0)                  | n.s     |
| pneumothorax                          | 5 (5)             | 0 (0)                  | n.s     |
| persistent pulmonary hypertension of the newborn | 9(9)              | 1 (9.1)                | n.s     |
| seizures                              | 4 (4)             | 0 (0)                  | n.s     |
| periventricular leukomalacia          | 1 (1)             | 0 (0)                  | n.s     |
| intra-periventricular hemorrhage      | 13(13)            | 4 (36.4)               | n.s     |
| hypovolemic & cerebroencephalopathy   | 3 (3)             | 1 (8.1)                | n.s     |
| septic shock                          | 3 (3)             | 2 (18.2)               | n.s     |
| multi organ failure                   | 1 (1)             | 0 (0)                  | n.s     |
| disseminated intravascular coagulation| 2 (2)             | 0 (0)                  | n.s     |
| renal failure                         | 5 (5)             | 1 (9.1)                | n.s     |
| mortality                             | 6 (6)             | 2 (18.2)               | n.s     |
| Length of hospitalization (d)         | 15                | 22                     | 0.039   |

Table 2: Clinical signs, therapy, morbidities, length of hospitalization of GBS and *E. coli* cases.

data are given as n (%), n.s= not significant. 1 data are given as median; 2 neonates who died within 3 days were excluded

Citation: Renoldner B, Hofer N, Resch B (2015) Early-Onset Neonatal Sepsis: Group B Streptococcal Compared to *E. coli* Disease. J Neonatal Biol 4: 201. doi:10.4172/2167-0897.1000201
to more likely react with hypothermia to a bacterial infection than term infants [16].

Limitations of this study include the relatively small study population and the long study time period, the retrospective design of the study even when data were collected carefully and the missing control group of uninfected neonates – the latter was not the aim of our study. Nevertheless our results are proven by larger studies in the field [1,15]. The long study time period enabled to demonstrate a global reduction in GBS disease. This might be the positive result of the risk-factor based GBS screening in Austria with subsequent intrapartum antibiotics therapy.

| Variable           | GBS cases (n=100) | E. coli cases (n=11) | P value |
|--------------------|------------------|----------------------|---------|
| CRP (mg/l)         |                  |                      |         |
| 1st day            | 25               | 50.2                 | n.s     |
| 2nd day            | 29               | 17.5                 | n.s     |
| 3rd day            | 22.6             | 12.85                | n.s     |
| White blood cell count (µL) |                 |                      |         |
| 1st day            | 13800            | 2400                 | n.s     |
| 2nd day            | 17400            | 17250                | n.s     |
| 3rd day            | 15190            | 14200                | n.s     |
| IT-Ratio           |                  |                      |         |
| 1st day            | 0.23             | 0.37                 | n.s     |
| 2nd day            | 0.24             | 0.21                 | n.s     |
| 3rd day            | 0.325            | 0.145                | n.s     |

Table 3: Laboratory parameters of GBS and E. coli cases.

Preventive strategies for E. coli sepsis might be based on risk factor analysis that identified chorioamnionitis and maternal fever occurring significantly more frequent in cases of E. coli infection. Despite a reduction of cases with GBS EOS over the study period vaccines for the prevention of GBS disease are urgently warranted and might further contribute to a reduction on the burden of GBS disease [17,18].

In conclusion our study confirmed that the main differences between GBS and E. coli sepsis were attributable to higher rates of preterm birth in the E. coli group. Laboratory data were not helpful in the differentiation of both pathogens.

References

1. Stoll BJ, Hansen NI, Sánchez PJ, Faix RG, Potindexter BR, et al. (2011) Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 127: 817-826.
2. Vergnano S, Sharland M, Kazembe P, Mwansambo C, Heath PT (2005) Neonatal sepsis: an international perspective. Arch Dis Child Fetal Neonatal Ed 90: F220-224.
3. Verani JR, McGee L, Schrag SJ (2010) Prevention of perinatal group B streptococcal disease-revised guidelines from CDC. MMWR Recomm Rep 59: 1-36.
4. Moser F (2011) Vorgehen zur Prophylaxe einer early onset sepsis des Neugeborenen durch beta-hämolysierende Streptokokken der Gruppe B (GBS) (hausinterner Vorgehensweise).
5. Abuzahra M (2009). Mutter-Kind-Pass: Ein internationaler Vergleich zu den Untersuchungen an schwangeren Frauen.
6. Moore MR, Schrag SJ, Schuchat A (2003) Effects of intrapartum antimicrobial prophylaxis for prevention of group-B streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 3: 201-213.
7. Towers CV, Carr MH, Padilla G, Asrat T (1998) Potential consequences of widespread antepartal use of ampicillin. Am J Obstet Gynecol 179: 879-883.
8. Terrone DA, Rinheart BK, Einstein MH, Britt LB, Martin JN Jr, et al. (1999) Neonatal sepsis and death caused by resistant Escherichia coli: possible consequences of extended maternal ampicillin administration. Am J Obstet Gynecol 180: 1345-1348.
9. Mercer BM, Carr TL, Beazley DD, Crouse DT, Sibai BM (1999) Antibiotic use in pregnancy and drug-resistant infant sepsis. Am J Obstet Gynecol 181: 816-821.
10. Goldstein B, Giroir B, Randolph A (2005) International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6: 2-8.
11. Hofer N, Zacharias E, Muller W, Resch B (2012) Performance of the definitions of the systemic inflammatory response syndrome and sepsis in neonates. J Perinat Med 40: 587-590.
12. Letsky EA (1999) Haematological values in the newborn. Textbook of neonatology Edinburgh: Churchill Livingstone.
13. Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG (2008) Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics 121: 689-696.
14. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, et al. (2002) Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 347: 240-247.
15. Mayor-Lynn K, González-Quintero VH, O'Sullivan MJ, Hartstein AI, Roger S, et al. (2005) Comparison of early-onset neonatal sepsis caused by Escherichia coli and group B Streptococcus. Am J Obstet Gynecol 192: 1437-1439.
16. Weisman LE, Stoll BJ, Cruess DF, Hall RT, Merenstein GB, et al. (1999) Neonatal sepsis: an international perspective. Arch Dis Child Fetal Neonat Ed 90: F220-224.
17. Baker CJ, Rench MA, McInnes P (2003) Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 21: 3468-3472.
18. Yang HH, Madoff LC, Guttormsen HK, Liu YD, Paoletti LC (2007) Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines. Infect Immun 7: 3455-3461.